

What is claimed is:

1. A compound which is crystalline carvedilol dihydrogen phosphate hemihydrate.
- 5 2. The compound according to claim 1 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta as shown in Figure 1.
- 10 3. The compound according to claim 2 having characteristic peaks from 0° degrees 2-theta (2θ) to 35° degrees 2-theta (2θ) at about 7.0 ± 0.2 (2θ), 11.4 ± 0.2 (2θ), 15.9 ± 0.2 (2θ), 18.8 ± 0.2 (2θ), 20.6 ± 0.2 (2θ), 22.8 ± 0.2 (2θ), and 25.4 ± 0.2 (2θ).
- 15 4. The compound according to claim 1 having an infrared spectrum which comprises characteristic absorption bands expressed in wave numbers as shown in Figure 6.
- 20 5. The compound according to claim 1 having a Raman spectrum which comprises characteristic peaks as shown in Figure 3.
6. A compound which is carvedilol dihydrogen phosphate dihydrate.
- 25 7. The compound according to claim 6 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (2θ) as shown in Figure 9.
- 30 8. The compound according to claim 7 having characteristic peaks from 0° degrees 2-theta (2θ) to 35° degrees 2-theta (2θ) at about 6.5 ± 0.2 (2θ), 7.1 ± 0.2 (2θ), 13.5 ± 0.2 (2θ), 14.0 ± 0.2 (2θ), 17.8 ± 0.2 (2θ), 18.9 ± 0.2 (2θ), and 21.0 ± 0.2 (2θ).

9. The compound according to claim 6 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (2θ) as shown in Figure 25.

5

10. The compound according to claim 9 having characteristic peaks from 0° degrees 2-theta (2θ) to 35° degrees 2-theta (2θ) at about 6.4 ± 0.2 (2θ), 9.6 ± 0.2 (2θ), 16.0 ± 0.2 (2θ), 18.4 ± 0.2 (2θ), 20.7 ± 0.2 (2θ), and 24.5 ± 0.2 (2θ).

10

11. A compound which is carvedilol dihydrogen phosphate methanol solvate.

12. The compound according to claim 11 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (2θ) as shown in Figure 24.

15

13. The compound according to claim 12 having characteristic peaks from 0° degrees 2-theta (2θ) to 35° degrees 2-theta (2θ) at about 6.9 ± 0.2 (2θ), 7.2 ± 0.2 (2θ), 13.5 ± 0.2 (2θ), 14.1 ± 0.2 (2θ), 17.8 ± 0.2 (2θ), and 34.0 ± 0.2 (2θ).

20

14. A compound which is carvedilol dihydrogen phosphate.

15. The compound according to claim 14 having an x-ray diffraction pattern which comprises characteristic peaks in degrees two-theta (2θ) as shown in Figure 28.

25

16. The compound according to claim 15 having characteristic peaks from 0° degrees 2-theta (2θ) to 35° degrees 2-theta (2θ) at about 13.2 ± 0.2 (2θ), 15.8 ± 0.2 (2θ), 16.3 ± 0.2 (2θ), 21.2 ± 0.2 (2θ), 23.7 ± 0.2 (2θ), and 26.0 ± 0.2 (2θ).

30

17. A compound which is carvedilol hydrogen phosphate.
18. The compound according to claim 17 having an x-ray
5 diffraction pattern which comprises characteristic peaks in degrees two-theta (2 θ) as shown in Figure 29.
19. The compound according to claim 18 having characteristic
peaks from 0° degrees 2-theta (2 θ) to 35° degrees 2-theta (2 θ) at about 5.5 \pm
10 0.2 (2 θ), 12.3 \pm 0.2 (2 θ), 15.3 \pm 0.2 (2 θ), 19.5 \pm 0.2 (2 θ), 21.6 \pm 0.2 (2 θ), and
24.9 \pm 0.2 (2 θ).
20. A pharmaceutical composition comprising the compound
according to claim 1 and a pharmaceutically acceptable carrier.
15
21. A pharmaceutical composition comprising the compound
according to claim 6 and a pharmaceutically acceptable carrier.
22. A pharmaceutical composition comprising the compound
20 according to claim 14 and a pharmaceutically acceptable carrier.
23. A pharmaceutical composition comprising the compound
according to claim 17 and a pharmaceutically acceptable carrier.
24. A method of treating hypertension, congestive heart failure
25 or angina which comprises administering to a subject in need thereof an
effective amount of the compound according to claim 1.
25. A method of treating hypertension, congestive heart failure
30 or angina which comprises administering to a subject in need thereof an
effective amount of the compound according to claim 6.

26. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 14.

5 27. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the compound according to claim 17.

10 28. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 20.

15 29. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 21.

20 30. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 22.

31. A method of treating hypertension, congestive heart failure or angina which comprises administering to a subject in need thereof an effective amount of the composition according to claim 23.